Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10629423 | 0.77 | RECQL (0.44) | RECQL | |
| SCHEMBL342416 | 0.74 | RECQL (0.53) | RECQL | |
| SCHEMBL28539568 | 0.73 | RECQL (0.49) | RECQL | |
| SCHEMBL5702076 | 0.73 | RECQL (0.51) | RECQL | |
| SCHEMBL27329281 | 0.73 | RECQL (0.51) | RECQL | |
| SCHEMBL662228 | 0.73 | RECQL (0.51) | RECQL | |
| SCHEMBL5702216 | 0.73 | RECQL (0.51) | RECQL | |
| SCHEMBL5082252 | 0.72 | RECQL (0.54) | RECQL | |
| SCHEMBL5265703 | 0.70 | RECQL (0.53) | RECQL | |
| Ammonia Solution, Strong SCHEMBL28441367 | 0.70 | RECQL (0.53) | RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240099976-A1 | BLENDED FORMULATIONS | SEQUESSOME TECHNOLOGY HOLDINGS LIMITED (MT) | 2024-03-28 | — | — | US | disclosed |
| US-20230017661-A1 | COMPOSITIONS AND MODULAR NANO- AND MICROPARTICLES FOR THE DELIVERY OF VARIOUS AGENTS AND USE THEREOF | VERI NANO INC. (US) | 2023-01-19 | — | — | US | disclosed |
| US-11547665-B2 | Multiphasic compositions | SEQUESSOME TECHNOLOGY HOLDINGS LIMITED (MT) | 2023-01-10 | — | — | US | disclosed |
| EP-3954361-A1 | MULTIPHASIC COMPOSITIONS | Sequessome Technology Holdings Limited (MT) | 2022-02-16 | — | — | EP | disclosed |
| US-20220031615-A1 | VESICLES | SEQUESSOME TECHNOLOGY HOLDINGS LIMITED (MT) | 2022-02-03 | — | — | US | disclosed |
| US-20210393655-A1 | Vesicular Formulations for Use in the Treatment of Pain or Reduced Mobility of a Joint | SEQUESSOME TECHNOLOGY HOLDINGS LIMITED (MT) | 2021-12-23 | — | — | US | disclosed |
| EP-3316857-B1 | MULTIPHASIC COMPOSITIONS | SEQUESSOME TECH HOLDINGS LIMITED (MT) | 2021-08-04 | — | — | EP | disclosed |
| WO-2021119464-A1 | COMPOSITIONS AND MODULAR NANO- AND MICROPARTICLES FOR THE DELIVERY OF VARIOUS AGENTS AND USE THEREOF | VERI NANO INC. (US) | 2021-06-17 | — | — | WO | disclosed |
| EP-3316856-B1 | BLENDED FORMULATIONS | SEQUESSOME TECH HOLDINGS LIMITED (MT) | 2021-04-07 | — | — | EP | disclosed |
| US-20210007989-A1 | MULTIPHASIC COMPOSITIONS | SEQUESSOME TECHNOLOGY HOLDINGS LIMITED (MT) | 2021-01-14 | — | — | US | disclosed |
| EP-1551370-B1 | AGGREGATE WITH INCREASED DEFORMABILITY, COMPRISING AT LEAST THREE AMPHIPATS, FOR IMPROVED TRANSPORT THROUGH SEMI-PERMEABLE BARRIERS AND FOR THE NON-INVASIVE DRUG APPLICATION IN VIVO, ESPECIALLY THROUGH THE SKIN | IDEA AG (DE) | 2007-12-19 | — | — | EP | disclosed |
| EP-1829527-A2 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2007-09-05 | — | — | EP | disclosed |
| EP-1829528-A2 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2007-09-05 | — | — | EP | disclosed |
| EP-1815846-A2 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2007-08-08 | — | — | EP | disclosed |
| EP-1815847-A2 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2007-08-08 | — | — | EP | disclosed |
| US-20070031483-A1 | Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | CEVC GREGOR | 2007-02-08 | — | — | US | disclosed |
| EP-1551370-A1 | AGGREGATE WITH INCREASED DEFORMABILITY, COMPRISING AT LEAST THREE AMPHIPATS, FOR IMPROVED TRANSPORT THROUGH SEMI-PERMEABLE BARRIERS AND FOR THE NON-INVASIVE DRUG APPLICATION IN VIVO, ESPECIALLY THROUGH THE SKIN | IDEA AG (DE) | 2005-07-13 | — | — | EP | disclosed |
| US-20040105881-A1 | Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2004-06-03 | — | — | US | disclosed |
| WO-2004032900-A1 | AGGREGATE WITH INCREASED DEFORMABILITY, COMPRISING AT LEAST THREE AMPHIPATS, FOR IMPROVED TRANSPORT THROUGH SEMI-PERMEABLE BARRIERS AND FOR THE NON-INVASIVE DRUG APPLICATION IN VIVO, ESPECIALLY THROUGH THE SKIN | IDEA AG (DE) | 2004-04-22 | — | — | WO | disclosed |
| US-20040071767-A1 | NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery | IDEA AG (DE) | 2004-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040071767-A1 | NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery | SLC43A1, TRPV2, TRPA1 | RECQL 2596/4885 |
| US-20070031483-A1 | Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | CUTA, ABCG2, PIGS | RECQL 622/4885 |
| US-20230017661-A1 | COMPOSITIONS AND MODULAR NANO- AND MICROPARTICLES FOR THE DELIVERY OF VARIOUS AGENTS AND USE THEREOF | CD47, CD44, CHMP4B | RECQL 548/4885 |
| US-20040105881-A1 | Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | CUTA, ABCG2, PIGS | RECQL 622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.